Results from Clinical Trials, Updated Financial Outlook, New Appointments, and Stock Option Grants - Research Report on Johnson

Results from Clinical Trials, Updated Financial Outlook, New Appointments, and
   Stock Option Grants - Research Report on Johnson & Johnson, Teva, CytRx,
                      Edwards Lifesciences, and Aegerion

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 16, 2013

NEW YORK, December 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA),
CytRx Corporation (NASDAQ: CYTR), Edwards Lifesciences Corp. (NYSE: EW) and
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Johnson & Johnson Research Report

On December 9, 2013, Johnson & Johnson's subsidiary, Janssen-Cilag
International NV announced that new data, presented at the 55th Annual Meeting
of the American Society for Hematology (ASH), continue to reinforce VELCADE's®
(bortezomib) role as the backbone of multiple myeloma treatment. According to
the Company, the data shows the survival benefits of higher cumulative dose
levels of VELCADE, exhibits significantly improved response rates and disease
progression when used in combination with dexamethasone, and demonstrates its
association with low rates of cardiotoxicity. Professor Maria-Victoria Mateos,
Consultant Physician of the Haematology Department at the University Hospital
of Salamanca, Spain and Lead Investigator on a study assessing higher dose
levels of bortezomib (ASH abstract 1968), said, "Bortezomib is at the core of
many multiple myeloma treatment regimens, yet our understanding of how best to
use it, and its full potential, continues to grow. The association between
higher cumulative dose levels of bortezomib and increased overall survival in
multiple myeloma patients receiving VELCADE-melphalan-prednisone is another
important potential step towards wider use of optimal treatment regimes. As
our understanding of the efficacy and safety of bortezomib develops so does
our ability to extend and improve the lives of patients with multiple
myeloma." The Full Research Report on Johnson & Johnson - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

Teva Pharmaceutical Industries Limited Research Report

On December 10, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced its
non-GAAP financial outlook for full-year 2014. The Company informed that it
expects net revenues of $19.3 billion to $20.3 billion, assuming the launch of
at least two AP-rated generic competitors to Copaxone® in the U.S. on June 1,
2014. Meanwhile, net revenue expectation of Teva ranges from $19.8 billion to
$20.8 billion, assuming absence of generic competition to Copaxone® in the
U.S. during 2014. Eyal Desheh, Acting President and CEO of Teva, commented "We
will continue to make significant progress in implementing our strategy. We
will focus our efforts on our generics business and core R&D programs,
including high-value complex generics, promising specialty medicines and New
Therapeutic Entities. In our specialty business, we anticipate six important
launches and the potential submission of ten additional medicines for
approval. At the same time, we are focused on increasing our organizational
effectiveness through our cost reduction program to ensure Teva's leadership
position, growth and sustainable profitability." The Full Research Report on
Teva Pharmaceutical Industries Limited - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/e3a3_TEVA

CytRx Corporation Research Report 

On December 11, 2013, CytRx Corp. (CytRx) announced highly positive top-line
efficacy results from a multicenter, randomized, open-label global Phase 2b
clinical trial. According to the Company, the trial investigated the efficacy
and safety of aldoxorubicin compared with doxorubicin in subjects with
first-line metastatic, locally advanced or unresectable soft tissue sarcomas
(STS). CytRx informed that the study showed an unambiguous 80-100% improvement
in progression-free survival (PFS) among patients treated with aldoxorubicin.
CytRx's President and CEO, Steven A. Kriegsman commented, "Aldoxorubicin is a
major advance for treating soft tissue sarcomas. We extend gratitude to the
investigators who so adeptly managed the conduct of this trial and to the
patients and their families who participated in it. These data prove that by
applying our proprietary linker technology to target the release of
doxorubicin directly at the site of cancer we are able to safely increase the
dosage of doxorubicin by approximately three and one-half to four times with
tremendous clinical benefit to the patient." The Full Research Report on CytRx
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at: 

http://www.analystscorner.com/r/full_research_report/1869_CYTR

Edwards Lifesciences Corp. Research Report 

On December 5, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences)
announced the appointment of Scott B. Ullem as the Company's next Corporate
Vice President, CFO, following the retirement of Thomas M. Abate. "Scott has
nearly 25 years of broad financial experience, proven leadership skills and a
successful record as CFO of a global public company," said Michael A.
Mussallem, Edwards' Chairman and CEO. "We are confident he will serve as a
valuable and passionate partner as our company continues its growth and
expands its leadership in innovative technologies for structural heart disease
and critical care patients in need." The Full Research Report on Edwards
Lifesciences Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/48b8_EW

Aegerion Pharmaceuticals, Inc. Research Report

On December 6, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that
it has granted stock options to purchase an aggregate of 15,800 shares of
common stock to six new employees under the inducement stock option program,
on December 2, 2013. According to the Company, each stock option has an
exercise price per share equal to $70.06. The Full Research Report on Aegerion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a3f6_AEGR

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.